Educational Series – Lenvatinib use in Hepatocellular Carcinoma: A Literature Review

We’re delighted to add our latest Educational Series which summarises the findings of eight key studies of lenvatinib as second-line or subsequent therapy in patients with hepatocellular carcinoma who failed previous immunotherapy, including atezolizumab plus bevacizumab. This review also presents the treatment approaches to hepatocellular carcinoma based on the Barcelona Clinic Liver Cancer staging system to improve overall survival.

Guiding commentary has been provided by Professor Simone Strasser, Head of Department and Senior Staff Specialist in the AW Morrow Gastroenterology and Liver Centre, and the Australian National Liver Transplant Unit at Royal Prince Alfred Hospital and the University of Sydney.